In-vitro activity of new sulphanilil fluoroquinolones against Staphylococcus aureus.
Two new quinolones, NSFQ-104 and NSFQ-105, derivatives of ciprofloxacin and norfloxacin with a 4-(4-aminophenylsulphonyl)-1-piperazinyl at position 7 showed better in-vitro activity against strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus than ciprofloxacin or norfloxacin. Their in-vitro activity was enhanced at pH 5.5.
Allemandi
D A
DA
Departamento de Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Argentina.
Alovero
F L
FL
Manzo
R H
RH
D000890:Anti-Infective Agents / Q000138:chemical synthesis / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology; D024841:Fluoroquinolones; D006801:Humans; D006863:Hydrogen-Ion Concentration; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D009643:Norfloxacin / Q000494:pharmacology; D015363:Quinolones / Q000138:chemical synthesis / Q000494:pharmacology*; D013203:Staphylococcal Infections / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*; D013997:Time Factors
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; C091355:NSFQ-104; C091356:NSFQ-105; D015363:Quinolones; D002939:Ciprofloxacin; D009643:Norfloxacin